Ikeda A, Nishimura K, Koyama H, Tsukino M, Izumi T
Second Department of Chest Disease Research Institute, Kyoto University, Japan.
Nihon Kyobu Shikkan Gakkai Zasshi. 1995 May;33(5):505-9.
To study the effects of an inhaled steroid on airway hyperresponsiveness (AHR) in chronic stable asthma, AHR was measured every month for 1 year in seven patients after their asthma had stabilized, i.e., when they had no wheezing or dyspnea, and their peak expiratory flow rates (PEFR) were at least 80 percent of the highest value. During the study period, no patient wheezed or had dyspnea, and daily variation in PEFR was less than 20 percent. In six patients, FEV1 was stable, and PEFR was always at least 80 percent of the highest value. AHR became less severe, by a factor of at least 2, in five of these six patients, but one patient's condition did not improve. The one patient whose PEFR fell below 80 percent of the highest value had more than a 4-fold increase in the severity of AHR. In conclusion, the severity of AHR can be reduced, even in patients with chronic stable asthma, if daily PEFR can be maintained in an optimal range by long-term use of inhaled corticosteroids.
为研究吸入性类固醇对慢性稳定期哮喘患者气道高反应性（AHR）的影响，在7例哮喘已稳定的患者中，即无喘息或呼吸困难且呼气峰值流速（PEFR）至少为最高值的80%时，连续1年每月测量一次AHR。在研究期间，无患者出现喘息或呼吸困难，PEFR的每日变化小于20%。6例患者的第一秒用力呼气容积（FEV1）稳定，PEFR始终至少为最高值的80%。这6例患者中有5例的AHR严重程度减轻至少2倍，但有1例患者病情未改善。PEFR低于最高值80%的那例患者，其AHR严重程度增加了4倍多。总之，对于慢性稳定期哮喘患者，若通过长期使用吸入性糖皮质激素使每日PEFR维持在最佳范围内，AHR的严重程度可降低。
